Investing News NetworkApril 29, 2024Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the 'Company' or 'Sona') announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the 'Study') which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response.

投资新闻网2024年4月29日，SONA Nanotech Inc.（CSE:SONA）（OTCQB:SNANF）（“公司”或“SONA”）宣布了Dalhousie大学当前研究中三阴性乳腺癌小鼠模型部分的进一步结果（“研究”），该研究证实了先前报道的肿瘤体积减少是由于肿瘤特异性全身免疫反应的激活。

These data relate to the follow-up biomarker analysis performed on the previously reported cohort of animals that showed a statistically significant synergistic effect in the shrinking of both treated and untreated tumors in animals bearing multiple tumors after treatment with the combination of Sona's targeted hyperthermia therapy ('THT') and interleukin-2 ('IL-2'), an immunotherapy agent widely used to treat human cancer patients.The fluorescence-activated cell sorting ('FACS') analysis of the tumor infiltrating cells looking at two panels of 12 biomarkers demonstrated a statistically significant cytotoxic T-cell infiltrate in both treated tumors and the untreated (contralateral) tumors, confirming a systemic immune response, consistent with an abscopal effect, in the treated mice treated with the combined THT and IL-2 therapy that is not seen in the other groups.

这些数据涉及对先前报道的动物队列进行的后续生物标志物分析，这些动物在使用Sona的靶向热疗（“THT”）和白细胞介素-2（“IL-2”）的组合治疗后，在携带多个肿瘤的动物中，在治疗和未治疗的肿瘤缩小方面显示出统计学上显着的协同作用，白细胞介素-2（“IL-2”）是一种广泛用于治疗人类癌症患者的免疫治疗剂。观察两组12种生物标志物的肿瘤浸润细胞的荧光激活细胞分选（“FACS”）分析表明，在治疗的肿瘤和未治疗的（对侧）肿瘤中，统计学上显着的细胞毒性T细胞浸润，证实了全身免疫应答，与远隔效应一致，在用联合THT和IL-2治疗的治疗小鼠中，其他组未见。

Also notable is the fact that cytotoxic T-cells in treated tumors express significantly more immune checkpoint indicating potential for additional benefits. Study Principal Investigator and Sona Advisory Board member, Dr. Carman Giacomantonio, comments, 'While our earlier data clearly showed that the Sona therapy achieved a synergistic effect in shrinking tumors when combined with IL-2, this follow-up analysis confirms our hypothesis that the effects were due to activation of a systemic immune response, and not just a .

同样值得注意的是，治疗肿瘤中的细胞毒性T细胞表达明显更多的免疫检查点，表明可能有额外的益处。研究首席研究员兼Sona咨询委员会成员Carman Giacomantonio博士评论道，“虽然我们之前的数据清楚地表明，当与IL-2联合使用时，Sona治疗在缩小肿瘤方面取得了协同作用，但这一后续分析证实了我们的假设，即这种作用是由于全身免疫反应的激活，而不仅仅是一种。